RNAZ Transcode Therapeutics Inc
Price (delayed)
$0.5285
Market cap
$276,512
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3,191.1
Enterprise value
-$1.45M
Highlights
The EPS has soared by 94% YoY and by 33% QoQ
Transcode Therapeutics's debt has plunged by 74% YoY and by 33% from the previous quarter
Transcode Therapeutics's equity has plunged by 63% YoY but it has increased by 25% from the previous quarter
The quick ratio has contracted by 38% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of RNAZ
Market
Valuations
Earnings
Shares outstanding
523,202
Market cap
$276,512
Enterprise value
-$1.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$14.63M
Net income
-$14.93M
EBIT
-$14.85M
EBITDA
-$14.29M
Free cash flow
-$15.87M
Per share
Balance sheet
Liquidity
EPS
-$3,191.1
EPS diluted
-$3,191.1
Free cash flow per share
-$35.67
Book value per share
$3.16
Revenue per share
$0
TBVPS
$8.85
Total assets
$3.94M
Total liabilities
$2.28M
Debt
$152,481
Equity
$1.65M
Working capital
$1.33M
Debt to equity
0.09
Current ratio
1.58
Quick ratio
0.83
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-281.4%
Return on equity
-649%
Return on invested capital
N/A
Return on capital employed
-898.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAZ stock price
How has the Transcode Therapeutics stock price performed over time
Intraday
-2.29%
1 week
-10.42%
1 month
-73.31%
1 year
-97.65%
YTD
-84.32%
QTD
6.77%
Financial performance
How have Transcode Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.63M
Net income
-$14.93M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 30% YoY and by 18% QoQ
Transcode Therapeutics's net income has increased by 24% YoY and by 17% from the previous quarter
Growth
What is Transcode Therapeutics's growth rate over time
Valuation
What is Transcode Therapeutics stock price valuation
P/E
N/A
P/B
0.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 94% YoY and by 33% QoQ
The price to book (P/B) is 95% lower than the last 4 quarters average of 3.4
Transcode Therapeutics's equity has plunged by 63% YoY but it has increased by 25% from the previous quarter
Efficiency
How efficient is Transcode Therapeutics business performance
The company's return on equity rose by 21% YoY but it fell by 9% QoQ
The company's return on assets fell by 8% QoQ and by 5% YoY
Dividends
What is RNAZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAZ.
Financial health
How did Transcode Therapeutics financials performed over time
The total assets is 72% more than the total liabilities
The total assets has plunged by 62% YoY and by 18% from the previous quarter
RNAZ's total liabilities has dropped by 61% year-on-year and by 35% since the previous quarter
Transcode Therapeutics's debt is 91% less than its equity
Transcode Therapeutics's debt has plunged by 74% YoY and by 33% from the previous quarter
Transcode Therapeutics's equity has plunged by 63% YoY but it has increased by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.